639 related articles for article (PubMed ID: 36401719)
21. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
22. Distinct antinociceptive and conditioned behavioral effects are produced by individual cannabinoids and a cannabis-derived mixture.
Morris T; Cucinello-Ragland JA; Marks TJ; Prevost K; Glenn JF; Davenport GJ; Edwards S; Winsauer PJ
Pharmacol Biochem Behav; 2024 Feb; 235():173692. PubMed ID: 38128766
[TBL] [Abstract][Full Text] [Related]
23. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
24. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
25. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
26. Beyond THC and Endocannabinoids.
Pacher P; Kogan NM; Mechoulam R
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():637-659. PubMed ID: 31580774
[TBL] [Abstract][Full Text] [Related]
27. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
28. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence.
Chye Y; Kirkham R; Lorenzetti V; McTavish E; Solowij N; Yücel M
Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jun; 6(6):627-635. PubMed ID: 32948510
[TBL] [Abstract][Full Text] [Related]
29. Current Cannabidiol Safety: A Review.
Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
[TBL] [Abstract][Full Text] [Related]
30. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
31. Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities.
Lal S; Shekher A; Puneet ; Narula AS; Abrahamse H; Gupta SC
Pharmacol Res; 2021 Jan; 163():105302. PubMed ID: 33246167
[TBL] [Abstract][Full Text] [Related]
32. Use of cannabinoids for the treatment of patients with post-traumatic stress disorder.
Forsythe ML; Boileau AJ
J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):121-132. PubMed ID: 33662194
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials.
D'Angelo M; Steardo L
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612415
[TBL] [Abstract][Full Text] [Related]
34. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
[No Abstract] [Full Text] [Related]
36. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
Newton M; Newton DW
J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
[No Abstract] [Full Text] [Related]
37. Human osteoclasts in vitro are dose dependently both inhibited and stimulated by cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC).
Nielsen SSR; Pedersen JAZ; Sharma N; Wasehuus PK; Hansen MS; Møller AMJ; Borggaard XG; Rauch A; Frost M; Sondergaard TE; Søe K
Bone; 2024 Apr; 181():117035. PubMed ID: 38342278
[TBL] [Abstract][Full Text] [Related]
38. Perceptions about THC and CBD effects among adults with and without prior cannabis experience.
Spinella TC; Bartholomeusz J; Stewart SH; Barrett SP
Addict Behav; 2023 Feb; 137():107508. PubMed ID: 36270038
[TBL] [Abstract][Full Text] [Related]
39. THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation.
Lamanna-Rama N; Romero-Miguel D; Casquero-Veiga M; MacDowell KS; Santa-Marta C; Torres-Sánchez S; Berrocoso E; Leza JC; Desco M; Soto-Montenegro ML
Psychiatry Res; 2024 Jan; 331():115643. PubMed ID: 38064909
[TBL] [Abstract][Full Text] [Related]
40. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
